Taylor & Francis

Taylor & Francis Group

Podcast by Taylor & Francis Group

  1. 1d ago

    Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway

    his podcast examines how hormone-sensitive prostate cancer (HSPC) is treated, specifically looking at therapies that target the androgen-sensitive pathway. Identification of patients and the clinical rationale for following different treatment pathways is reviewed, including examination of the current treatment options for both metastatic HSPC (mHSPC) and nonmetastatic HSPC, and consideration of barriers that might exist for optimal treatment. The importance of selecting a treatment strategy that offers control of the disease but allows the patient to maintain their functionality and quality of life is discussed, with an emphasis that, for patients with high-risk biochemical recurrence or mHSPC, combination treatment with androgen deprivation therapy and an androgen receptor pathway inhibitor is the standard of care that should be considered unless contraindicated. Plain Language Summary This podcast examines how a type of advanced prostate cancer called hormone‑sensitive prostate cancer (HSPC) is treated. The importance of identifying patients with different stages of cancer is discussed; for example, whether the cancer is metastatic, meaning it has spread to other parts of the body, or non-metastatic, meaning that it hasn’t spread. This information can then be used to guide treatment choices. Current treatment options for different stages of the disease are explored, including the importance of choosing a treatment that provides effective control of the cancer but does not negatively impact the patient’s quality of life. Published in Future Oncology - https://doi.org/10.1080/14796694.2025.2561320

    Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway

Ratings & Reviews

5
out of 5
2 Ratings

About

Podcast by Taylor & Francis Group